About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

AbTherx and Mosaic Biosciences Forge Exclusive Partnership to Provide Milestone and Royalty-Free Access to AbTherx's Premier Human Antibody Discovery Technology

  • Mosaic becomes the exclusive provider of antibody discovery services using AbTherx's Atlas™ Full Human Diversity Mouse

  • Streamlined milestone- and royalty-free access with flexible engagement options

  • End-to-end program integration from in vivodiscovery through candidate selection, creating a single, premium path to the clinic

MOUNTAIN VIEW, CA AND BOULDER CO / ACCESS Newswire / September 17, 2025 / AbTherx and Mosaic Biosciences today announced a strategic agreement under which Mosaic will be the exclusive provider of antibody discovery services using AbTherx's Atlas Full Human Diversity (FHD) Transgenic Mouse. The collaboration establishes a unified pathway for biotech and biopharma partners to launch discovery campaigns powered by the FHD platform, with Mosaic providing a seamless, end-to-end experience from immunization through candidate nomination. The partnership also introduces a milestone- and royalty-free access model, providing greater flexibility and operational efficiency for teams advancing new therapeutics.

This collaboration brings together industry-leading platforms in a fully integrated discovery program, offering drug developers two complementary routes to antibody generation. Partners can now pair in vivo discovery using AbTherx's advanced FHD transgenic platform with Mosaic's in vitro engine-including phage and yeast display for de novo discovery and rapid lead optimization-plus engineering, functional assays, and developability. The result is broader epitope coverage, greater sequence diversity, and higher-quality therapeutic candidates, all supported by continuous data flow and fewer vendor touchpoints.

"This is about giving innovators a more streamlined path to high-quality therapeutic candidates," said Eric Furfine, PhD, CESO, Mosaic Biosciences. "With exclusive access to the Full Human Diversity mouse paired with Mosaic's downstream engineering, functional assays, and developability capabilities, our partners benefit from a single integrated path from design and immunization through candidate nomination. We're combining discovery breadth with operational clarity-and our milestone- and royalty-free option helps make budgets more predictable."

"AbTherx has become the market leader in developing innovative human transgenic technologies for therapeutic antibody discovery," said Justin Mika, CEO, AbTherx. "By granting Mosaic exclusive service rights to our Full Human Diversity platform, we're enabling drug developers to engage a quality-driven, ex-pharma team and benefit from a consistent, efficient experience from discovery through selection. The combination of in vivo and in vitroapproaches maximizes sequence and epitope diversity, improves reliability and speed, and ultimately increases the likelihood of program success."

The Atlas Full Human Diversity Mouse is engineered to capture a broad, human-like antibody repertoire by sourcing VH and VK alleles that represent >99% of expressed human sequences and boost productive B-cell rearrangement to deliver human-like diversity by using functional VH and VK components only and excluding pseudogenes and other non-productive alleles. The transgenes were carefully curated to avoid patented alleles and rare/ethnic variants that could elevate immunogenicity or IP risk, creating a next-generation platform that improves upon the functional and freedom-to-operate limitations of other models.

Through this partnership, AbTherx and Mosaic will coordinate scientific support and technology transfer to ensure consistent, high-quality execution across the discovery workflow.

About AbTherx

AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit www.abtherx.com.

About Mosaic Biosciences

Mosaic Biosciences is pioneering a transformative model for drug discovery, offering biotech, biopharma, and academic institutions a fully integrated platform for therapeutic discovery, characterization, and optimization, specializing in protein therapeutics. Mosaic's approach seamlessly incorporates essential screening, such as developability assessment and advanced cell-based assays, into the discovery process, ensuring that potential therapeutics are evaluated for their practical application from the outset. Mosaic's partners also benefit from rapid evaluations of animal pharmacokinetic and pharmacodynamic studies, allowing for swift decision-making. With access to cutting-edge proprietary tools and data-driven methodologies, Mosaic's nimble, multidisciplinary team of experienced scientists collaborates closely with partners to deliver innovative solutions to modern drug discovery. United by a shared commitment to advancing human health, Mosaic empowers partners to achieve therapeutic breakthroughs efficiently and effectively. For more information, please visit www.mosaicbio.com.

AbTherx Media Contact

Stacey Borders
stacey@abtherx.com

Mosaic Biosciences Media Contact

Chrissy Conti
chrissy@mosaicbio.com

SOURCE: AbTherx, Inc



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.